These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 8670328)
1. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity. Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328 [TBL] [Abstract][Full Text] [Related]
2. Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. Kao AH; Navratil JS; Ruffing MJ; Liu CC; Hawkins D; McKinnon KM; Danchenko N; Ahearn JM; Manzi S Arthritis Rheum; 2010 Mar; 62(3):837-44. PubMed ID: 20187154 [TBL] [Abstract][Full Text] [Related]
3. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus. Senaldi G; Makinde VA; Vergani D; Isenberg DA Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693 [TBL] [Abstract][Full Text] [Related]
4. Urinary C3d is elevated in patients with active Lupus nephritis and a fall in its level after 3 months predicts response at 6 months on follow up. Ganguly S; Majumder S; Kumar S; Gupta R; Muhammed H; Shobha V; Aggarwal A; Misra R Lupus; 2020 Nov; 29(13):1800-1806. PubMed ID: 32807020 [TBL] [Abstract][Full Text] [Related]
5. Complement Alternative Pathway׳s Activation in Patients With Lupus Nephritis. Song D; Guo WY; Wang FM; Li YZ; Song Y; Yu F; Zhao MH Am J Med Sci; 2017 Mar; 353(3):247-257. PubMed ID: 28262211 [TBL] [Abstract][Full Text] [Related]
6. Assessment of disease activity and impending flare in patients with systemic lupus erythematosus. Comparison of the use of complement split products and conventional measurements of complement. Buyon JP; Tamerius J; Belmont HM; Abramson SB Arthritis Rheum; 1992 Sep; 35(9):1028-37. PubMed ID: 1418018 [TBL] [Abstract][Full Text] [Related]
7. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway. Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367 [TBL] [Abstract][Full Text] [Related]
8. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Julkunen H; Ekblom-Kullberg S; Miettinen A Rheumatol Int; 2012 Aug; 32(8):2445-51. PubMed ID: 21706294 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of complement activation products in Chinese patients with systemic lupus erythematosus. Li J; An L; Zhang Z Clin Exp Rheumatol; 2014; 32(1):48-53. PubMed ID: 23981509 [TBL] [Abstract][Full Text] [Related]
11. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Ho A; Barr SG; Magder LS; Petri M Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976 [TBL] [Abstract][Full Text] [Related]
12. Complement split product C3d as an indicator of disease activity in systemic lupus erythematosus. Röther E; Lang B; Coldewey R; Hartung K; Peter HH Clin Rheumatol; 1993 Mar; 12(1):31-5. PubMed ID: 8467609 [TBL] [Abstract][Full Text] [Related]
13. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Kerr LD; Adelsberg BR; Schulman P; Spiera H Arthritis Rheum; 1989 Nov; 32(11):1406-13. PubMed ID: 2818657 [TBL] [Abstract][Full Text] [Related]
14. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Buyon JP; Tamerius J; Ordorica S; Young B; Abramson SB Arthritis Rheum; 1992 Jan; 35(1):55-61. PubMed ID: 1731815 [TBL] [Abstract][Full Text] [Related]
15. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity. Kim AHJ; Strand V; Sen DP; Fu Q; Mathis NL; Schmidt MJ; Bruchas RR; Staten NR; Olson PK; Stiening CM; Atkinson JP Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950 [TBL] [Abstract][Full Text] [Related]
16. Urine neopterin as a parameter of disease activity in patients with systemic lupus erythematosus: comparisons with serum sIL-2R and antibodies to dsDNA, erythrocyte sedimentation rate, and plasma C3, C4, and C3 degradation products. Lim KL; Jones AC; Brown NS; Powell RJ Ann Rheum Dis; 1993 Jun; 52(6):429-35. PubMed ID: 8323394 [TBL] [Abstract][Full Text] [Related]
17. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis? Lood C; Eriksson S; Gullstrand B; Jönsen A; Sturfelt G; Truedsson L; Bengtsson AA Lupus; 2012 Nov; 21(13):1423-32. PubMed ID: 22878256 [TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Liu CC; Kao AH; Hawkins DM; Manzi S; Sattar A; Wilson N; Ahearn JM Clin Transl Sci; 2009 Aug; 2(4):300-8. PubMed ID: 20161444 [TBL] [Abstract][Full Text] [Related]
19. Reduced numbers of complement receptor type 1 on erythrocytes are associated with increased levels of anticardiolipin antibodies. Findings in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Hammond A; Rudge AC; Loizou S; Bowcock SJ; Walport MJ Arthritis Rheum; 1989 Mar; 32(3):259-64. PubMed ID: 2522783 [TBL] [Abstract][Full Text] [Related]
20. Glomerular c4d staining can be an indicator of disease activity in lupus nephritis. Sahin OZ; Gurses S; Taslı F; Yavas H; Ersoy R; Uzum A; Cirit M Ren Fail; 2013; 35(2):222-5. PubMed ID: 23176021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]